APA (7th ed.) Citation

Adasme, M. F., Parisi, D., Van Belle, K., Salentin, S., Haupt, V. J., Jennings, G. S., . . . Schroeder, M. (2020). Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PLoS ONE, 15(5), 1. https://doi.org/10.1371/journal.pone.0233089

Chicago Style (17th ed.) Citation

Adasme, Melissa F., et al. "Structure-based Drug Repositioning Explains Ibrutinib as VEGFR2 Inhibitor." PLoS ONE 15, no. 5 (2020): 1. https://doi.org/10.1371/journal.pone.0233089.

MLA (9th ed.) Citation

Adasme, Melissa F., et al. "Structure-based Drug Repositioning Explains Ibrutinib as VEGFR2 Inhibitor." PLoS ONE, vol. 15, no. 5, 2020, p. 1, https://doi.org/10.1371/journal.pone.0233089.